Sanofi infant vaccine gets EU approval
PARIS (Reuters) - French drug maker Sanofi SA said on Monday the European Commission has approved its primary and booster vaccine for infants from six weeks of age.
The vaccine protects infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type B.
The new vaccine will be commercialized by Sanofi Pasteur, the vaccines division of Sanofi, under the brand name Hexyon in Western Europe and Hexacima in Eastern Europe.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- U.S. immigration protesters drop U.S. border blockade plan
- Secret Service investigates after man jumps White House fence, reaches doors
- About 60,000 Syrian Kurds flee to Turkey from Islamic State advance |
- Kentucky firefighter dies after ice bucket challenge accident